ロフェコキシブ (Japanese Wikipedia)

McClellan, Frank (2008). “The Vioxx Litigation: A Critical Look at Trial Tactics, the Tort System, and the Roles of Lawyers in Mass Tort Litigation”. DePaul Law Review 57: 509–38. SSRN 1861337.

tamu.edu

dimer.tamu.edu

[3] Archived June 10, 2012, at the Wayback Machine.

theage.com.au

“Drug unfit for sale, says judge in compo case”. The Age (Melbourne) 4 January 2015閲覧。

thenalfa.org

“$315M Fee Allocation Dispure in Vioxx class actionThe NALFA”. Thenalfa.org. 4 January 2015閲覧。

tremeaurx.com

“Tremeau Pharmaceuticals News”. Tremeau Pharmaceuticals. 2021年10月7日閲覧。

uscourts.gov

laed.uscourts.gov

“Vioxx Product Liability”. Laed.uscourts.gov. 4 January 2015閲覧。

web.archive.org

Knox, Richard (September 30, 2004), Merck Pulls Arthritis Drug Vioxx from Market, オリジナルのNovember 11, 2010時点におけるアーカイブ。 December 24, 2016閲覧。
“NAME OF DRUG: Rofecoxib (MK-0966) : Memorandum”. Fda.gov. 24 March 2015時点のオリジナルよりアーカイブ。4 January 2015閲覧。
Martin, John S. (September 5, 2006). “Report of John S. Martin, Jr. to the Special Committee of the Board of Directors of Merck & Co., Inc. Concerning the Conduct of Senior Management in the Development and Marketing of Vioxx: Appendix H”. Debevoise & Plimpton LLP. p. 2. December 20, 2010時点のオリジナルよりアーカイブ。2021年10月7日閲覧。
http://www.powerlinefacts.com/Sciam_article_on_lobbying.htm Industry groups are fighting government regulation by formenting scientific uncertainty at the Wayback Machine (archived June 6, 2012^{[Date mismatch]})
[1] Archived June 25, 2006, at the Wayback Machine.
[3] Archived June 10, 2012, at the Wayback Machine.
[4] Archived September 8, 2006, at the Wayback Machine.
“Consultation NDA 21-042. Cardiovascular and Renal Safety database.”. Food and Drug Administration: Centre for Drug Evaluation and Research:Division of Cardio-Renal Drug Products, HFD-110. p. 4 (April 30, 1999). March 10, 2010時点のオリジナルよりアーカイブ。2021年10月7日閲覧。
“NAME OF DRUG: Rofecoxib (MK-0966) : Memorandum”. Fda.gov. 18 December 2001時点のオリジナルよりアーカイブ。4 January 2015閲覧。
“European Medicines Agency concludes action on COX-2 inhibitors”. European Medicines Agency. 2008年4月6日時点のオリジナルよりアーカイブ。2008年4月16日閲覧。
“Merck Announces Voluntary Worldwide Withdrawal of VIOXX”. Merck.com. 17 April 2012時点のオリジナルよりアーカイブ。4 January 2015閲覧。
“The Journal : Current Issue”. web.archive.org (2004年11月7日). 2021年10月7日閲覧。
[6] Archived September 21, 2015, at the Wayback Machine.
“Vioxx judge steps in to split $350 ml plaintiffs lawyer pie”. Reuters. (11 August 2011). オリジナルの23 December 2011時点におけるアーカイブ。 4 January 2015閲覧。
[7] Archived November 24, 2011, at the Wayback Machine.
“Tremeau Expands Leadership Team”. 2021年10月7日閲覧。
“Tremeau to Exhibit at HTRS in May”. 2021年10月7日閲覧。

wikipedia.org

en.wikipedia.org

McClellan, Frank (2008). “The Vioxx Litigation: A Critical Look at Trial Tactics, the Tort System, and the Roles of Lawyers in Mass Tort Litigation”. DePaul Law Review 57: 509–38. SSRN 1861337.

worldcat.org

search.worldcat.org

Ushiyama, Shigeru; Yamada, Tomoko; Murakami, Yukiko; Kumakura, Sei-ichiro; Inoue, Shin-ichi; Suzuki, Keisuke; Nakao, Akira; Kawara, Akihiro et al. (2008-01-06). “Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects”. European Journal of Pharmacology 578 (1): 76–86. doi:10.1016/j.ejphar.2007.08.034. ISSN 0014-2999. PMID 17920584.
McGettigan, Patricia; Henry, David (2011-09-27). “Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies”. PLOS Medicine 8 (9): e1001098. doi:10.1371/journal.pmed.1001098. ISSN 1549-1676. PMC 3181230. PMID 21980265.
Coxib traditional NSAID Trialists' (CNT) Collaboration (August 2013). “Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials”. The Lancet 382 (9894): 769–779. doi:10.1016/s0140-6736(13)60900-9. ISSN 0140-6736. PMC 3778977. PMID 23726390.
Patrono, Carlo; Baigent, Colin (2014-02-25). “Nonsteroidal Anti-Inflammatory Drugs and the Heart”. Circulation 129 (8): 907–916. doi:10.1161/circulationaha.113.004480. ISSN 0009-7322. PMID 24566065.
Nissen, Steven E.; Yeomans, Neville D.; Solomon, Daniel H.; Lüscher, Thomas F.; Libby, Peter; Husni, M. Elaine; Graham, David Y.; Borer, Jeffrey S. et al. (2016-12-29). “Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis”. New England Journal of Medicine 375 (26): 2519–2529. doi:10.1056/nejmoa1611593. ISSN 0028-4793. PMID 27959716.
Forsyth, Angela; Witkop, Michelle; Lambing, Angela; Garrido, Cesar; Dunn, Spencer; Cooper, David L.; Nugent, Diane (October 2015). “Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study”. Patient Preference and Adherence 9: 1549–1560. doi:10.2147/PPA.S87659. ISSN 1177-889X. PMC 4631419. PMID 26604708.

ロフェコキシブ (Japanese Wikipedia)

beasleyallen.com

bloomberg.com

bmj.com

books.google.com

case.edu

genetics.case.edu

chron.com

cnn.com

money.cnn.com

doi.org

duke.edu

web.duke.edu

europa.eu

emea.europa.eu

fda.gov

fda.gov

accessdata.fda.gov

forbes.com

genome.jp

ijdvl.com

insurancejournal.com

mdconsult.com

medicinenet.com

merck.com

mit.edu

tech.mit.edu

nbcnews.com

news-medical.net

newscientist.com

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

nikkeibp.co.jp

medical.nikkeibp.co.jp

npr.org

nytimes.com

pbs.org

pharmexec.com

powerlinefacts.com

reuters.com

blogs.reuters.com

reuters.com

saferdrugsnow.org

sciencemag.org

blogs.sciencemag.org

semanticscholar.org

ssrn.com

tamu.edu

dimer.tamu.edu

theage.com.au

thenalfa.org

tremeaurx.com

uscourts.gov

laed.uscourts.gov

web.archive.org

wikipedia.org

en.wikipedia.org

worldcat.org

search.worldcat.org

wsj.com

wsj.com

blogs.wsj.com